


Novel heterocyclically substituted amides, their preparation and use

5 We claim:

1. An amide of the general formula I

10



15

and its tautomeric and isomeric forms, possible enantiomeric and diastereomeric forms, as well as possible physiologically tolerable salts, in which the variables have the following

20 meanings:


- R¹ can be phenyl, naphthyl, quinolyl, pyridyl, pyrimidyl, pyrazyl [sic], pyridazyl, imidazolyl, thiazole, quinazyl, isoquinolyl, quinazyl [sic], quinoxalyl, thienyl, benzothienyl, benzofuranyl, furanyl, and indolyl, where the rings can be additionally substituted by up to 3 radicals R⁵,
- R² is chlorine, bromine, fluorine, C₁-C₆-alkyl, C₁-C₆-alkenyl, C₁-C₆-alkynyl, C₁-C₆-alkylphenyl, C₁-C₆-alkenylphenyl, C₁-C₆-alkynylphenyl, phenyl, NHCO-C₁-C₄-alkyl, NHSO₂-C₁-C₄-alkyl, -NHCophenyl [sic], -NHCO-naphthyl, NO₂, -O-C₁-C₄-alkyl and NH₂, where the aromatic rings can additionally carry one or two radicals R⁵ and two radicals R² together can also be a chain -CH=CH-CH=CH- and thus form a fused benzo ring, which for its part can be substituted by one R⁵ and
- R³ is -C₁-C₆-alkyl, which is branched or unbranched, and which can additionally carry an S-CH₃ radical or a phenyl, cyclohexyl, cycloheptyl, cyclopentyl, indolyl, pyridyl or naphthyl ring which for its part is substituted by by [sic] at most two radicals R⁵, where R⁵ is hydrogen, C₁-C₄-alkyl, which is branched or unbranched, -O-C₁-C₄-alkyl, OH, Cl, F, Br, I, CF₃, NO₂, NH₂, CN, COOH, COO-C₁-C₄-alkyl, -NHCO-C₁-C₄-alkyl, -NHCO-phenyl, -NHCO-C₁-C₄-alkyl,

50

-NHSO₂-phenyl, -SO₂-C₁-C₄-alkyl, -(CH₂)_n-NR¹²R¹³ and
-SO₂-phenyl,

- X is a bond, -(CH₂)_m-, -(CH₂)_m-O-(CH₂)_o-, -(CH₂)_o-S-(CH₂)_m-
5 [sic], -(CH₂)_o-SO-(CH₂)_m-, -(CH₂)_o-SO₂-(CH₂)_m-, -CH=CH-, -C≡C-,
-CO-CH=CH-, -(CH₂)_o-CO-(CH₂)_m-, -(CH₂)_m-NHCO-(CH₂)_o-,
-(CH₂)_m-CONH-(CH₂)_o-, -(CH₂)_m-NHSO₂-(CH₂)_o-, -NH-CO-CH=CH-,
-(CH₂)_m-SO₂NH-(CH₂)_o-, -CH=CH-CONH- and


10




- 15 and in the case of CH=CH double bonds can be either the E or the
Z form and

R¹-X together are also

20



and




and

25

Y is an unsaturated heterocyclic ring such as pyridine,
pyrimidine, pyrazine, imidazole and thiazole and

- R⁴ is hydrogen, COOR⁶ and CO-Z, in which Z is NR⁷R⁸, and is
30




35

R⁶ is hydrogen, C₁-C₆-alkyl, which is linear or branched, and
which can be substituted by a phenyl ring which itself can
additionally be substituted by one or two radicals R⁹, and

- 40 R⁷ is hydrogen, C₁-C₆-alkyl, which is branched and unbranched,
and

R⁸ is hydrogen, C₁-C₆-alkyl, which is branched or unbranched
which can additionally be substituted by a phenyl ring which
45 can additionally carry a radical R⁹, and by

51



and

- 10 R^9 can be hydrogen, C_1 - C_4 -alkyl, which is branched or unbranched, $-O$ - C_1 - C_4 -alkyl, OH, Cl, F, Br, I, CF_3 , NO_2 , NH_2 , CN, COOH, COO - C_1 - C_4 -alkyl, $-NHCO$ - C_1 - C_4 -alkyl, $-NHCO$ -phenyl, $-NHSO_2$ - C_1 - C_4 -alkyl, $-NHSO_2$ -phenyl, $-SO_2$ - C_1 - C_4 -alkyl and $-SO_2$ -phenyl

15

R^{10} is hydrogen, C_1 - C_6 -alkyl, which is linear or branched, and which can be substituted by a phenyl ring which itself can additionally be substituted by one or two radicals R^9 , and

- 20 R^{11} is hydrogen, C_1 - C_6 -alkyl, which is linear or branched, and which can be substituted by a phenyl ring which itself can additionally be substituted by one or two radicals R^9 , and

n is a number 0, 1 or 2, and

25

m, o independently of one another is a numeral 0, 1, 2, 3 or 4.

2. An amide of the formula I as claimed in claim 1, where

- 30 R^3 is benzyl, $CH_2CH_2CH_2CH_3$, $CH_2CH_2CH_2CH_2CH_3$ and

Y is pyridine and

R^4 is $CO-NR^7NR^8$ and

35

R^7 is hydrogen

R^8 is CH_2CH_2 , $CH_2CH_2CH_2$, $CH_2CH_2CH_2CH_2$ and

- 40 R^9 is hydrogen and

n is 0 and 1 and

all remaining variables have the same meanings as in claim 1.

45

3. An amide of the formula I as claimed in claim 1, where

R³ is benzyl, CH₂CH₂CH₂CH₃, CH₂CH₂CH₂CH₂CH₃ and

Y is pyridine and

5 R⁴ is hydrogen and

R⁹ is hydrogen

n is 0 and 1 and

10

all remaining variables have the same meanings as in claim 1.

4. An amide of the formula I as claimed in claim 1, where

15 R³ is benzyl, CH₂CH₂CH₂CH₃, CH₂CH₂CH₂CH₂CH₃ and

Y is imidazole and thiazole and

R⁴ is CO-NR⁷NR⁸ and

20

R⁷ is hydrogen

R⁸ is CH₂CH₂, CH₂CH₂CH₂, CH₂CH₂CH₂CH₂ and

25 R⁹ is hydrogen and

n is 0 and 1 and

all remaining variables have the same meanings as in claim 1.

30

5. An amide of the formula I as claimed in claim 1, where

R³ is benzyl, CH₂-pyridine, CH₂CH₂CH₂CH₃, CH₂CH₂CH₂CH₂CH₃ and

35 Y is imidazole and thiazole and

R⁴ is hydrogen and

R⁹ is hydrogen and

40

n is 0 and 1 and

all remaining variables have the same meanings as in claim 1.

45 6. The use of amides of the formula I as claimed in claim [sic]
1-5 for the treatment of diseases.

7. The use of amides of the formula I as claimed in claim [sic] 1-5 as inhibitors of cysteine proteases.
8. The use as claimed in claim 6 as inhibitors of cysteine proteases such as calpains and cathepsins, in particular calpains I and II and cathepsins B and L.
9. The use of amides of the formula I as claimed in claim [sic] 1-5 for the production as [sic] pharmaceuticals for the treatment of diseases in which increased calpain activity occurs.
10. The use of amides of the formula I as claimed in claim [sic] 1-5 for the production of pharmaceuticals for the treatment of neurodegenerative diseases and neuronal damage.
11. The use as claimed in claim 9 for the treatment of those neurodegenerative diseases and that neuronal damage which is caused by ischemia, trauma or mass hemorrhages.
12. The use as claimed in claim 10 for the treatment of cerebral stroke and craniocerebral trauma.
13. The use as claimed in claim 10 for the treatment of Alzheimer's disease and Huntington's disease.
14. The use as claimed in claim 10 for the treatment of epilepsy.
15. The use of the compounds of the formula I as claimed in claim [sic] 1-5 for the production of pharmaceuticals and treatment of damage to the heart after cardiac ischemias, reperfusion damage after vascular occlusion, damage to the kidneys after renal ischemias, skeletal muscular damage, muscular dystrophies, damage which results due to proliferation of the smooth muscle cells, coronary vasospasm, cerebral vasospasm, cataracts of the eyes and restenosis of the blood vessels after angioplasty.
16. The use of the amides of the formula I as claimed in claim [sic] 1-5 for the production of pharmaceuticals for treating tumors and metastasis thereof.
17. The use of the amides of the formula I as claimed in claim [sic] 1-5 for the production of pharmaceuticals for treating diseases in which increased interleukin-1 levels occur.

18. The use of the amides as claimed in claim [sic] 1-5 for treating immunological diseases such as inflammations and rheumatic disorders.

5 19. A pharmaceutical preparation for oral, parenteral and intraperitoneal use, comprising per individual dose, in addition to the customary pharmaceutical auxiliaries, at least of [sic] one amide I as claimed in claim [sic] 1-5.

10

15

20

25

30

35

40

45